Literature DB >> 23487275

Alcohol consumption, alcohol dependence and related harms in Spain, and the effect of treatment-based interventions on alcohol dependence.

Jürgen Rehm1, Maximilien X Rehm, Kevin D Shield, Gerrit Gmel, Antoni Gual.   

Abstract

Alcohol consumption in Spain has traditionally followed the Mediterranean drinking pattern, featuring daily drinking with meals, beer as the preferred beverage, and comparatively little drinking to intoxication. Alcohol dependence (AD), one of the most detrimental disorders caused by alcohol, was prevalent in 0.2% of women and 1.2% of men, corresponding to 31,200 women and 186,000 men in Spain with AD in 2005 in the age group of 15 to 64 year. These prevalence estimates of alcohol dependence are likely underestimated due to limitations in the World Mental Health Survey which cannot be fully corrected for; however, the estimates of AD for Spain represent the most accurate and up to date estimates available. Alcohol creates a significant health burden in Spain with 11.3 premature deaths in women per 100,000 aged 15 to 64 years, and 40.9 premature deaths in men per 100,000 in the same age group were due to alcohol consumption (data for 2004). This amounts to 8.4% of all female deaths and 12.3% of all the male deaths in this age group being attributable to alcohol consumption. A large percentage of these harms were due to heavy alcohol consumption and AD. AD is undertreated in Spain, with less than 10% of all people with AD treated. For those who are treated, psychotherapy is the most utilized form of treatment to avoid relapse. If 40% of AD patients in Spain were treated with pharmacological treatment (the most effective treatment method), 2.2% of female and 6.2% of male deaths due to AD would be prevented within one year. Thus by increasing treatment rates is an important means of reducing the alcohol-attributable mortality and health burden in Spain.

Entities:  

Mesh:

Year:  2013        PMID: 23487275

Source DB:  PubMed          Journal:  Adicciones        ISSN: 0214-4840            Impact factor:   2.979


  7 in total

1.  Optimizing strategies to reduce alcohol consumption and relapses, improving abstinence in liver transplant recipients.

Authors:  Isabel Legaz; Manuel Muro
Journal:  Hepatobiliary Surg Nutr       Date:  2022-02       Impact factor: 7.293

2.  Using the SF-6D to measure the impact of alcohol dependence on health-related quality of life.

Authors:  Jacinto Mosquera Nogueira; Eva Rodríguez-Míguez
Journal:  Eur J Health Econ       Date:  2014-09-06

3.  The effects of capping the alcohol consumption distribution and relative risk functions on the estimated number of deaths attributable to alcohol consumption in the European Union in 2004.

Authors:  Gerrit Gmel; Kevin D Shield; Tara A K Kehoe-Chan; Jürgen Rehm
Journal:  BMC Med Res Methodol       Date:  2013-02-18       Impact factor: 4.615

4.  Birth-sex cohort alcohol use transitions in the general population: the cross-sectional PEGASUS-Murcia project.

Authors:  Mathilde M Husky; Chrianna Bharat; Gemma Vilagut; Diego Salmerón; Salvador Martínez; Carmen Navarro; Jordi Alonso; Ronald C Kessler; Fernando Navarro-Mateu
Journal:  Adicciones       Date:  2020-04-01       Impact factor: 4.102

5.  Alcohol consumption, alcohol dependence, and related mortality in Italy in 2004: effects of treatment-based interventions on alcohol dependence.

Authors:  Kevin D Shield; Jürgen Rehm; Gerrit Gmel; Maximilien X Rehm; Allaman Allamani
Journal:  Subst Abuse Treat Prev Policy       Date:  2013-06-13

6.  Development, Validation, and Implementation of an Innovative Mobile App for Alcohol Dependence Management: Protocol for the SIDEAL Trial.

Authors:  Pablo Barrio; Lluisa Ortega; Xavier Bona; Antoni Gual
Journal:  JMIR Res Protoc       Date:  2016-02-17

7.  [Detection and prevalence of alcohol use disorders in primary health care in Catalonia].

Authors:  Laia Miquel; Pablo Barrio; Jose Moreno-España; Lluisa Ortega; Jakob Manthey; Jürgen Rehm; Antoni Gual
Journal:  Aten Primaria       Date:  2015-10-09       Impact factor: 1.137

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.